International Myeloma working group recommendations for the diagnosis and management of Myeloma-Related Renal Impairment

Meletios A. Dimopoulos, Pieter Sonneveld, Nelson Leung, Giampaolo Merlini, Heinz Ludwig, Efstathios Kastritis, Hartmut Goldschmidt, Douglas Joshua, Robert Z. Orlowski, Raymond Powles, David H. Vesole, Laurent Garderet, Hermann Einsele, Antonio Palumbo, Michele Cavo, Paul G. Richardson, Philippe Moreau, Jeśus San Miguel, S Vincent Rajkumar, Brian G M DurieEvangelos Terpos

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

Purpose The aim of the International Myeloma Working Group was to develop practical recommendations for the diagnosis and management of multiple myeloma-related renal impairment (RI). Methods Recommendations were based on published data through December 2015, and were developed using the system developed by the Grading of Recommendation, Assessment, Development, and Evaluation Working Group. Recommendations All patients with myeloma at diagnosis and at disease assessment should have serum creatinine, estimated glomerular filtration rate, and electrolytes measurements as well as free light chain, if available, and urine electrophoresis of a sample from a 24-hour urine collection (grade A). The Chronic Kidney Disease Epidemiology Collaboration, preferably, or the Modification of Diet in Renal Disease formula should be used for the evaluation of estimated glomerular filtration rate in patients with stabilized serum creatinine (grade A). International Myeloma Working Group criteria for renal reversibility should be used (grade B). For themanagement of RI in patientswithmultiplemyeloma, high fluid intake is indicated along with antimyeloma therapy (grade B). The use of high-cutoff hemodialysis membranes in combination with antimyeloma therapy can be considered (grade B). Bortezomib-based regimens remain the cornerstone of the management of myeloma-related RI (grade A). High-dose dexamethasone should be administered at least for the first month of therapy (grade B). Thalidomide is effective in patients with myeloma with RI, and no dose modifications are needed (grade B). Lenalidomide is effective and safe, mainly in patients with mild to moderate RI (grade B); for patients with severe RI or on dialysis, lenalidomide should be given with closemonitoring for hematologic toxicity (grade B) with dose reduction as needed. High-dose therapy with autologous stem cell transplantation (with melphalan 100 mg/m2 to 140 mg/m2) is feasible in patients with RI (grade C). Carfilzomib can be safely administered to patients with creatinine clearance . 15 mL/min, whereas ixazomib in combination with lenalidomide and dexamethasone can be safely administered to patients with creatinine clearance . 30 mL/min (grade A).

Original languageEnglish (US)
Pages (from-to)1544-1557
Number of pages14
JournalJournal of Clinical Oncology
Volume34
Issue number13
DOIs
StatePublished - May 1 2016
Externally publishedYes

Fingerprint

Kidney
Creatinine
Glomerular Filtration Rate
Dexamethasone
Diet Therapy
Urine Specimen Collection
Melphalan
Thalidomide
Stem Cell Transplantation
Therapeutics
Serum
Multiple Myeloma
Chronic Renal Insufficiency
Electrolytes
Renal Dialysis
Electrophoresis
Dialysis
Epidemiology
Urine
Light

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Dimopoulos, M. A., Sonneveld, P., Leung, N., Merlini, G., Ludwig, H., Kastritis, E., ... Terpos, E. (2016). International Myeloma working group recommendations for the diagnosis and management of Myeloma-Related Renal Impairment. Journal of Clinical Oncology, 34(13), 1544-1557. https://doi.org/10.1200/JCO.2015.65.0044

International Myeloma working group recommendations for the diagnosis and management of Myeloma-Related Renal Impairment. / Dimopoulos, Meletios A.; Sonneveld, Pieter; Leung, Nelson; Merlini, Giampaolo; Ludwig, Heinz; Kastritis, Efstathios; Goldschmidt, Hartmut; Joshua, Douglas; Orlowski, Robert Z.; Powles, Raymond; Vesole, David H.; Garderet, Laurent; Einsele, Hermann; Palumbo, Antonio; Cavo, Michele; Richardson, Paul G.; Moreau, Philippe; Miguel, Jeśus San; Rajkumar, S Vincent; Durie, Brian G M; Terpos, Evangelos.

In: Journal of Clinical Oncology, Vol. 34, No. 13, 01.05.2016, p. 1544-1557.

Research output: Contribution to journalArticle

Dimopoulos, MA, Sonneveld, P, Leung, N, Merlini, G, Ludwig, H, Kastritis, E, Goldschmidt, H, Joshua, D, Orlowski, RZ, Powles, R, Vesole, DH, Garderet, L, Einsele, H, Palumbo, A, Cavo, M, Richardson, PG, Moreau, P, Miguel, JS, Rajkumar, SV, Durie, BGM & Terpos, E 2016, 'International Myeloma working group recommendations for the diagnosis and management of Myeloma-Related Renal Impairment', Journal of Clinical Oncology, vol. 34, no. 13, pp. 1544-1557. https://doi.org/10.1200/JCO.2015.65.0044
Dimopoulos, Meletios A. ; Sonneveld, Pieter ; Leung, Nelson ; Merlini, Giampaolo ; Ludwig, Heinz ; Kastritis, Efstathios ; Goldschmidt, Hartmut ; Joshua, Douglas ; Orlowski, Robert Z. ; Powles, Raymond ; Vesole, David H. ; Garderet, Laurent ; Einsele, Hermann ; Palumbo, Antonio ; Cavo, Michele ; Richardson, Paul G. ; Moreau, Philippe ; Miguel, Jeśus San ; Rajkumar, S Vincent ; Durie, Brian G M ; Terpos, Evangelos. / International Myeloma working group recommendations for the diagnosis and management of Myeloma-Related Renal Impairment. In: Journal of Clinical Oncology. 2016 ; Vol. 34, No. 13. pp. 1544-1557.
@article{a0ec32ed8ef24a268ba00e2ac8b30deb,
title = "International Myeloma working group recommendations for the diagnosis and management of Myeloma-Related Renal Impairment",
abstract = "Purpose The aim of the International Myeloma Working Group was to develop practical recommendations for the diagnosis and management of multiple myeloma-related renal impairment (RI). Methods Recommendations were based on published data through December 2015, and were developed using the system developed by the Grading of Recommendation, Assessment, Development, and Evaluation Working Group. Recommendations All patients with myeloma at diagnosis and at disease assessment should have serum creatinine, estimated glomerular filtration rate, and electrolytes measurements as well as free light chain, if available, and urine electrophoresis of a sample from a 24-hour urine collection (grade A). The Chronic Kidney Disease Epidemiology Collaboration, preferably, or the Modification of Diet in Renal Disease formula should be used for the evaluation of estimated glomerular filtration rate in patients with stabilized serum creatinine (grade A). International Myeloma Working Group criteria for renal reversibility should be used (grade B). For themanagement of RI in patientswithmultiplemyeloma, high fluid intake is indicated along with antimyeloma therapy (grade B). The use of high-cutoff hemodialysis membranes in combination with antimyeloma therapy can be considered (grade B). Bortezomib-based regimens remain the cornerstone of the management of myeloma-related RI (grade A). High-dose dexamethasone should be administered at least for the first month of therapy (grade B). Thalidomide is effective in patients with myeloma with RI, and no dose modifications are needed (grade B). Lenalidomide is effective and safe, mainly in patients with mild to moderate RI (grade B); for patients with severe RI or on dialysis, lenalidomide should be given with closemonitoring for hematologic toxicity (grade B) with dose reduction as needed. High-dose therapy with autologous stem cell transplantation (with melphalan 100 mg/m2 to 140 mg/m2) is feasible in patients with RI (grade C). Carfilzomib can be safely administered to patients with creatinine clearance . 15 mL/min, whereas ixazomib in combination with lenalidomide and dexamethasone can be safely administered to patients with creatinine clearance . 30 mL/min (grade A).",
author = "Dimopoulos, {Meletios A.} and Pieter Sonneveld and Nelson Leung and Giampaolo Merlini and Heinz Ludwig and Efstathios Kastritis and Hartmut Goldschmidt and Douglas Joshua and Orlowski, {Robert Z.} and Raymond Powles and Vesole, {David H.} and Laurent Garderet and Hermann Einsele and Antonio Palumbo and Michele Cavo and Richardson, {Paul G.} and Philippe Moreau and Miguel, {Jeśus San} and Rajkumar, {S Vincent} and Durie, {Brian G M} and Evangelos Terpos",
year = "2016",
month = "5",
day = "1",
doi = "10.1200/JCO.2015.65.0044",
language = "English (US)",
volume = "34",
pages = "1544--1557",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "13",

}

TY - JOUR

T1 - International Myeloma working group recommendations for the diagnosis and management of Myeloma-Related Renal Impairment

AU - Dimopoulos, Meletios A.

AU - Sonneveld, Pieter

AU - Leung, Nelson

AU - Merlini, Giampaolo

AU - Ludwig, Heinz

AU - Kastritis, Efstathios

AU - Goldschmidt, Hartmut

AU - Joshua, Douglas

AU - Orlowski, Robert Z.

AU - Powles, Raymond

AU - Vesole, David H.

AU - Garderet, Laurent

AU - Einsele, Hermann

AU - Palumbo, Antonio

AU - Cavo, Michele

AU - Richardson, Paul G.

AU - Moreau, Philippe

AU - Miguel, Jeśus San

AU - Rajkumar, S Vincent

AU - Durie, Brian G M

AU - Terpos, Evangelos

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Purpose The aim of the International Myeloma Working Group was to develop practical recommendations for the diagnosis and management of multiple myeloma-related renal impairment (RI). Methods Recommendations were based on published data through December 2015, and were developed using the system developed by the Grading of Recommendation, Assessment, Development, and Evaluation Working Group. Recommendations All patients with myeloma at diagnosis and at disease assessment should have serum creatinine, estimated glomerular filtration rate, and electrolytes measurements as well as free light chain, if available, and urine electrophoresis of a sample from a 24-hour urine collection (grade A). The Chronic Kidney Disease Epidemiology Collaboration, preferably, or the Modification of Diet in Renal Disease formula should be used for the evaluation of estimated glomerular filtration rate in patients with stabilized serum creatinine (grade A). International Myeloma Working Group criteria for renal reversibility should be used (grade B). For themanagement of RI in patientswithmultiplemyeloma, high fluid intake is indicated along with antimyeloma therapy (grade B). The use of high-cutoff hemodialysis membranes in combination with antimyeloma therapy can be considered (grade B). Bortezomib-based regimens remain the cornerstone of the management of myeloma-related RI (grade A). High-dose dexamethasone should be administered at least for the first month of therapy (grade B). Thalidomide is effective in patients with myeloma with RI, and no dose modifications are needed (grade B). Lenalidomide is effective and safe, mainly in patients with mild to moderate RI (grade B); for patients with severe RI or on dialysis, lenalidomide should be given with closemonitoring for hematologic toxicity (grade B) with dose reduction as needed. High-dose therapy with autologous stem cell transplantation (with melphalan 100 mg/m2 to 140 mg/m2) is feasible in patients with RI (grade C). Carfilzomib can be safely administered to patients with creatinine clearance . 15 mL/min, whereas ixazomib in combination with lenalidomide and dexamethasone can be safely administered to patients with creatinine clearance . 30 mL/min (grade A).

AB - Purpose The aim of the International Myeloma Working Group was to develop practical recommendations for the diagnosis and management of multiple myeloma-related renal impairment (RI). Methods Recommendations were based on published data through December 2015, and were developed using the system developed by the Grading of Recommendation, Assessment, Development, and Evaluation Working Group. Recommendations All patients with myeloma at diagnosis and at disease assessment should have serum creatinine, estimated glomerular filtration rate, and electrolytes measurements as well as free light chain, if available, and urine electrophoresis of a sample from a 24-hour urine collection (grade A). The Chronic Kidney Disease Epidemiology Collaboration, preferably, or the Modification of Diet in Renal Disease formula should be used for the evaluation of estimated glomerular filtration rate in patients with stabilized serum creatinine (grade A). International Myeloma Working Group criteria for renal reversibility should be used (grade B). For themanagement of RI in patientswithmultiplemyeloma, high fluid intake is indicated along with antimyeloma therapy (grade B). The use of high-cutoff hemodialysis membranes in combination with antimyeloma therapy can be considered (grade B). Bortezomib-based regimens remain the cornerstone of the management of myeloma-related RI (grade A). High-dose dexamethasone should be administered at least for the first month of therapy (grade B). Thalidomide is effective in patients with myeloma with RI, and no dose modifications are needed (grade B). Lenalidomide is effective and safe, mainly in patients with mild to moderate RI (grade B); for patients with severe RI or on dialysis, lenalidomide should be given with closemonitoring for hematologic toxicity (grade B) with dose reduction as needed. High-dose therapy with autologous stem cell transplantation (with melphalan 100 mg/m2 to 140 mg/m2) is feasible in patients with RI (grade C). Carfilzomib can be safely administered to patients with creatinine clearance . 15 mL/min, whereas ixazomib in combination with lenalidomide and dexamethasone can be safely administered to patients with creatinine clearance . 30 mL/min (grade A).

UR - http://www.scopus.com/inward/record.url?scp=84965050407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965050407&partnerID=8YFLogxK

U2 - 10.1200/JCO.2015.65.0044

DO - 10.1200/JCO.2015.65.0044

M3 - Article

C2 - 26976420

AN - SCOPUS:84965050407

VL - 34

SP - 1544

EP - 1557

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 13

ER -